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Background
Syndromes involving unexplained chronic widespread pain
(CWP) and multi-system symptoms are common, with 1-
5% prevalence for fibromyalgia alone. They more often
affect females and cause disability and high costs [1-3].
Other common syndromes include chronic fatigue, sero-
negative Lyme, and Gulf War Illness. Fragmentary syn-
dromes include TMJD, POTS, CRPS, irritable bowel).
These syndromes are particularly devastating in children
and young adults, where they interfere with education and
development and disrupt entire families [4-6]. SFPN is
known to cause CWP and multi-system complaints in
older adults. Unlike the syndromes above, SFPN can be
objectively diagnosed by measuring innervation in lower-
leg skin biopsies, and autonomic functions testing (AFT)
of heart rate, blood pressure and sweating [7]. SFPN has
several established causes including diabetes, infections,
cancer, and toxins. Many causes are diagnosable, treatable,
and sometimes curable [8]. Our work suggests that unrec-
ognized SFPN contributes to several syndromes involving
CWP and multi-organ symptoms.
Materials and methods
With IRB permission, we retrospective analyzed the medi-
cal records of 41 patients with onset of unexplained CWP
and multisymptoms before age 21; most had objective
testing for SFPN [9]. We also prospectively studied 27
adult patients with fibromyalgia and 30 healthy volunteers
using history, examination, skin biopsies and AFT [10].
Results
Retrospective chart review identified definite (in 59%) and
probable SFPN (in 17%) among the young patients with
onset before age 21 [9]. We characterized the clinical fea-
tures, diagnostic, and treatment options for this new early-
onset SFPN. Studying children, who lacked the typical
causes of late-onset SFPN, implicated autoimmune causal-
ity in most. Among patients treated with immunomodula-
tory therapies, pain and other symptoms improved in 2/3
[9]. Among adults with fibromyalgia, 41% of skin biopsies
from subjects with fibromyalgia vs. 3% of biopsies from
controls were diagnostic for SFPN, and symptom and
examination scores were higher in fibromyalgia subjects
than in controls (all P ≤ 0.001) [10]. All fibromyalgia
patients diagnosed with SFPN then had blood tests for all
known causes [8]. None had diabetes but 62% had test-
results consistent with dysimmunity, and some had
genetic causes [10]. Other laboratories have now also
linked fibromyalgia to SFPN [11-15].
Conclusions
Some patients with unexplained widespread pain and
multi-system syndromes such as fibromyalgia have objec-
tively diagnosable SFPN. SFPN can affect children and
young adults, not just older adults. Multiple lines of evi-
dence suggest that early-onset SFPN has novel causes that
can be treated. The prevalence of SFPN among TMJD
patients is unstudied.
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